S

Steven A. Rosenberg

National Cancer Institute

ORCID: 0000-0002-8939-8910

Publishes on Immunotherapy and Immune Responses, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers. 1.6k papers and 198.2k citations.

PubIndex Score98Top 2%How it's scored

🌟#1 Current Senior Leader in CAR-T cell therapy research 🌟#1 Current Senior Leader in Immunotherapy and Immune Responses 🌟#6 Current Senior Leader in Cancer Immunotherapy and Biomarkers 🌟#6 Current Senior Leader in Chemotherapy-related skin toxicity

1.6kPublications

198.2kTotal Citations

#1in CAR-T cell therapy research

First publication: 1953First senior author: 1966

Immunotherapy and Immune Responses CAR-T cell therapy research Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction Virus-based gene therapy research

Top publicationsby citations

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Mark E. Dudley, Steven A. Rosenberg|Journal of Clinical Oncology|2008

Cited by 1.3k

IL-2: The First Effective Immunotherapy for Human Cancer

Steven A. Rosenberg|The Journal of Immunology|2014

Cited by 1.3k

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

Alena Gros, Steven A. Rosenberg|Journal of Clinical Investigation|2014

Cited by 1.1k

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Paul F. Robbins, Steven A. Rosenberg|The Journal of Experimental Medicine|1996

Cited by 547

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Gal Cafri, Steven A. Rosenberg|Journal of Clinical Investigation|2020

Cited by 409